Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

MedXY Editorial Team•Oct 14, 2025•Hematology-Oncology

Azacitidine, a hypomethylating agent traditionally used in myelodysplastic syndrome (MDS), demonstrates significant efficacy in reducing inflammation and cytopenias in VEXAS syndrome patients.
Over 60% of patients achieved inflammatory response with notable hematologic improvements, and a majority showed molecular evidence of reduced UBA1 mutant clone burden.
Relapse rates were low during continued azacitidine therapy, and re-exposure to azacitidine was effective in most cases after relapse upon discontinuation.
Adverse events such as infections and cytopenias were common but predominantly occurred early in treatment, indicating an acceptable and manageable safety profile.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Azacitidine, a hypomethylating agent traditionally used in myelodysplastic syndrome (MDS), demonstrates significant efficacy in reducing inflammation and cytopenias in VEXAS syndrome patients.
Over 60% of patients achieved inflammatory response with notable hematologic improvements, and a majority showed molecular evidence of reduced UBA1 mutant clone burden.
Relapse rates were low during continued azacitidine therapy, and re-exposure to azacitidine was effective in most cases after relapse upon discontinuation.
Adverse events such as infections and cytopenias were common but predominantly occurred early in treatment, indicating an acceptable and manageable safety profile.